A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Trial Profile

A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 09 Jan 2017 Results of population pharmacokinetic analysis (n=600) from one phase II clinical trial (NCT00918255) and two phase III clinical trials (NCT01468207 and NCT01468233) assessing the effects of potential covariates on adalimumab pharmacokinetics, published in the Clinical Pharmacokinetics journal.
    • 21 Oct 2013 New trial record
    • 04 Oct 2013 A post-hoc analysis of this study, which uses the novel Hidradenitis Suppurativa Clinical Response (HiSCR) endpoint, has been presented at the 22nd Congress of the European Dermatology and Venereology, according to an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top